OptiNose Temettü

Temettü kriter kontrolleri 0/6

OptiNose şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-54.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-54.7%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Slammed 34% OptiNose, Inc. (NASDAQ:OPTN) Screens Well Here But There Might Be A Catch

Sep 27

Market Cool On OptiNose, Inc.'s (NASDAQ:OPTN) Revenues Pushing Shares 30% Lower

Aug 11

Not Many Are Piling Into OptiNose, Inc. (NASDAQ:OPTN) Stock Yet As It Plummets 42%

Apr 27

There's Reason For Concern Over OptiNose, Inc.'s (NASDAQ:OPTN) Massive 32% Price Jump

Mar 01

Revenues Working Against OptiNose, Inc.'s (NASDAQ:OPTN) Share Price

Dec 28

OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 29%

May 23

The Consensus EPS Estimates For OptiNose, Inc. (NASDAQ:OPTN) Just Fell Dramatically

Mar 09

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: OPTN şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: OPTN şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

OptiNose Piyasaya Karşı Temettü Getirisi

OPTN temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (OPTN)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.6%
Sektör Ortalaması (Pharmaceuticals)	2.3%
Analist tahmini (OPTN) (3 yıla kadar)	n/a

Önemli Temettü: OPTN şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, OPTN şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: OPTN şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: OPTN herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

OptiNose Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

OptiNose Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

New minor risk - Market cap size

Optinose Appoints Terry Kohler as Chief Financial Officer

Slammed 34% OptiNose, Inc. (NASDAQ:OPTN) Screens Well Here But There Might Be A Catch

Consensus EPS estimates upgraded to US$0.23 loss, revenue downgraded

Market Cool On OptiNose, Inc.'s (NASDAQ:OPTN) Revenues Pushing Shares 30% Lower

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

OptiNose, Inc. to Report Q2, 2024 Results on Aug 08, 2024

CEO & Director recently sold US$127k worth of stock

CEO & Director notifies of intention to sell stock

OptiNose, Inc.(NasdaqGS:OPTN) dropped from Russell Small Cap Completeness Index

OptiNose, Inc. announced that it has received $4.68 million in funding

Consensus estimates of losses per share improve by 12%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

OptiNose, Inc. to Report Q1, 2024 Results on May 14, 2024

OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024

OptiNose, Inc., Annual General Meeting, Jun 06, 2024

Not Many Are Piling Into OptiNose, Inc. (NASDAQ:OPTN) Stock Yet As It Plummets 42%

OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025

New minor risk - Share price stability

Price target increased by 7.1% to US$3.75

Full year 2023 earnings: EPS exceeds analyst expectations

OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024

New minor risk - Share price stability

There's Reason For Concern Over OptiNose, Inc.'s (NASDAQ:OPTN) Massive 32% Price Jump

OptiNose, Inc. to Report Q4, 2023 Results on Mar 07, 2024

CEO & Director recently sold US$69k worth of stock

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology

Forecast to breakeven in 2026

Revenues Working Against OptiNose, Inc.'s (NASDAQ:OPTN) Share Price

New minor risk - Share price stability

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

OptiNose, Inc. Revises Revenue Guidance for the Full Year of 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

OptiNose, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Consensus estimates of losses per share improve by 31%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

OptiNose, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New minor risk - Profitability

Price target decreased by 16% to US$3.50

No longer forecast to breakeven

OptiNose, Inc. Approves Board Changes

OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 29%

Consensus EPS estimates fall by 20%, revenue upgraded

Optinose, Inc. Provides Revenue Guidance for Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE

The Consensus EPS Estimates For OptiNose, Inc. (NASDAQ:OPTN) Just Fell Dramatically

Full year 2022 earnings: EPS misses analyst expectations

Optinose Announces Board Changes

CEO & Director recently sold US$53k worth of stock

Optinose Announces Departure of Michele Janis as Acting Chief Financial Officer

No longer forecast to breakeven

OptiNose, Inc. has completed a Follow-on Equity Offering in the amount of $50.008 million.

Consensus revenue estimates fall by 13%

High number of new directors

Price target decreased to US$6.60

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

OptiNose, Inc. Provides Revenue Guidance for the Full Year 2022

OptiNose, Inc. Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting

OptiNose, Inc. to Report Q3, 2022 Results on Nov 10, 2022

CEO & Director notifies of intention to sell stock

CEO & Director recently sold US$190k worth of stock

High number of new directors

OptiNose, Inc. Provides Revenue Guidance for the Full Year of 2022

OptiNose GAAP EPS of -$0.23 beats by $0.01, revenue of $20.6M misses by $0.9M

OptiNose, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Optinose Announces XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program

Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

OptiNose: Potential Winner In Chronic Sinusitis Treatment

Optinose Announces Positive Top-Line Results of Reopen2, Its Second Phase 3 Clinical Trial of Xhance for Treatment of Chronic Sinusitis

OptiNose, Inc. Announces Executive Appointments

Optinose, Inc. Updates Revenue Guidance for 2022

OptiNose, Inc. to Report Q1, 2022 Results on May 12, 2022